Lord, Abbett & Co. LLC Castle Biosciences Inc Transaction History

Lord, Abbett & Co. LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$16.0 - $45.99 $3.28 Million - $9.43 Million	-205,036 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$33.17 - $46.98 $1.53 Million - $2.17 Million	46,226 Added 29.11%	205,036 $9.2 Million
Q4 2021 Feb 11, 2022	SELL	$39.06 - $67.58 $60,543 - $104,749	-1,550 Reduced 0.97%	158,810 $6.81 Million
Q3 2021 Nov 09, 2021	BUY	$60.13 - $77.6 $3.74 Million - $4.83 Million	62,260 Added 63.47%	160,360 $10.7 Million
Q2 2021 Aug 11, 2021	SELL	$50.07 - $76.78 $4.77 Million - $7.32 Million	-95,349 Reduced 49.29%	98,100 $7.19 Million
Q1 2021 May 11, 2021	SELL	$58.92 - $97.33 $1.43 Million - $2.36 Million	-24,227 Reduced 11.13%	193,449 $13.2 Million
Q4 2020 Feb 09, 2021	BUY	$43.6 - $73.05 $1.55 Million - $2.6 Million	35,608 Added 19.56%	217,676 $14.6 Million
Q3 2020 Nov 12, 2020	BUY	$38.47 - $52.03 $812,832 - $1.1 Million	21,129 Added 13.13%	182,068 $9.37 Million
Q2 2020 Aug 14, 2020	BUY	$27.28 - $43.01 $651,173 - $1.03 Million	23,870 Added 17.41%	160,939 $6.07 Million
Q1 2020 May 14, 2020	SELL	$23.08 - $35.53 $949,211 - $1.46 Million	-41,127 Reduced 23.08%	137,069 $4.09 Million
Q4 2019 Feb 14, 2020	BUY	$15.74 - $35.04 $2.8 Million - $6.24 Million	178,196 New	178,196 $6.13 Million

171

25.5M

511K

130K

Ticker CSTL
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 26,297,000
Market Cap $750M
Description
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

Stay updated on Lord, Abbett & Co. LLC with notifications on news.